New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint

International Journal of Cardiology

Volumn 196, Issue , 2015, Pages 133-138

  Rubboli, Andrea ^a   Agewall, Stefan ^b   Huber, Kurt ^c   Lip, Gregory Y H ^d  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF OSLO   (Norway)

^c WILHELMINEN HOSPITAL   (Austria)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Non vitamin K antagonist oral anticoagulants; Percutaneous coronary intervention; Stent; Triple therapy; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDOTE; APIXABAN; CLOPIDOGREL; DABIGATRAN; DAREXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DRUG COMBINATION; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; TICLOPIDINE;

BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DUAL ANTIPLATELET THERAPY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); NEW-ONSET ATRIAL FIBRILLATION; PATIENT RISK; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS CORONARY INTERVENTION WITH STENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIPLE THERAPY; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; DRUG COMBINATION; STENT; THROMBOSIS;

ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; ATRIAL FIBRILLATION; DABIGATRAN; DRUG COMBINATIONS; FACTOR XA INHIBITORS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; STENTS; THROMBOSIS; TICLOPIDINE; WARFARIN;

EID: 84937509798     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.06.006     Document Type: Review

References (49)

1. G.Y. Lip, S. Windecker, K. Huber, and et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur. Heart J. 35 2014 3155 3179
2. S. Agewall, M. Cattaneo, J.P. Collet ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy Eur. Heart J. 34 2013 1708 1713
3. S. Schulman New oral anticoagulant agents - general features and outcomes in subsets of patients Thromb. Haemost. 111 2014 575 582
4. S.J. Connolly, M.D. Ezekowitz, S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
5. M.R. Patel, K.W. Mahaffey, J. Garg ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 889
6. C.B. Granger, J.H. Alexander, J.J. McMurray ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
7. A. Rubboli, D.P. Faxon, K.E. Airaksinen, and et al. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview Thromb. Haemost. 112 2014 1080 1087
8. H.J. Zhao, Z.T. Zheng, Z.H. Wang, and et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment Chest 139 2011 260 267
9. P.P. Singh, M. Singh, U. Bedi, J. Molnar, R. Arora, and S. Khosla Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation Ther. Adv. Cardiovasc. Dis. 5 2011 23 31
10. J.G. Andrade, M.W. Deyell, C. Khoo, M. Lee, K. Humphries, and J.A. Cairns Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis Can. J. Cardiol. 29 2013 204 212
11. S. Brulotte, M. Sénéchal, P. Poirier, and et al. Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute Can. J. Cardiol. 23 Suppl. B 2007 80B 83B
12. K.L. Olson, T. Delate, S.G. Johnson, E.D. Wilson, and D.M. Witt Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention J. Thromb. Thrombolysis 29 2010 316 321
13. A. Sambola, I. Ferreira-González, J. Angel, and et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study Heart 95 2009 1483 1488
14. E. Nikolsky, R. Mehran, G.D. Dangas, and et al. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial) Am. J. Cardiol. 109 2012 831 838
15. A. Rubboli, P. Magnavacchi, P. Guastaroba, and et al. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry) Am. J. Cardiol. 109 2012 1411 1417
16. A. Rubboli, F. Saia, A. Sciahbasi WARfarin and Coronary STENTing (WAR-STENT) Study Group Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry J. Invasive Cardiol. 26 2014 563 569
17. J.H. Alexander, R.D. Lopes, S. James APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome N. Engl. J. Med. 365 2011 699 708
18. J. Oldgren, L. Wallentin, J.H. Alexander, and et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis Eur. Heart J. 34 2013 1670 1680
19. A.L. Dans, S.J. Connolly, L. Wallentin, and et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
20. ACTIVE Writing Group of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
21. J.L. Mega, E. Braunwald, S.D. Wiviott ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome N. Engl. J. Med. 366 2012 9 19
22. J.P. Bassand Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis EuroIntervention 9 2014 1333 1341
23. C.M. Gibson, R. Mehran, C. Bode, and et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) Am. Heart J. 169 2015 472 478
24. G. Palareti, W. Ageno, A. Ferrari, and et al. Clinical management of rivaroxaban-treated patients Expert. Opin. Pharmacother. 14 2013 655 667
25. I. Ahrens, C. Bode, and A. Zirlik Anticoagulation during and after acute coronary syndrome Hamostaseologie 34 2014 72 77
26. G. Palareti, and B. Cosmi Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients Thromb. Haemost. 102 2009 268 278
27. A. Majeed, H.G. Hwang, S.J. Connolly, and et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin Circulation 128 2013 2325 2332
28. C. Held, E.M. Hylek, J.H. Alexander, and et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial Eur. Heart J. 36 2015 1264 1272
29. J. Beyer-Westendorf, K. Förster, S. Pannach, and et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Blood 124 2014 955 962
30. A. Gomez-Outes, M.L. Suarez-Gea, R. Lecumberri, A.I. Terleira-Fernandez, and E. Vargas-Castrillon Specific antidotes in development for reversal of novel anticoagulants: a review Recent Pat. Cardiovasc. Drug Discov. 9 2014 2 10
31. D.M. Siegal, and M.A. Crowther Acute management of bleeding in patients on novel oral anticoagulants Eur. Heart J. 34 2013 489 500
32. A.J. Camm, G.Y. Lip, R. De Caterina ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 19 47
33. S. Apostolakis, R.M. Sullivan, B. Olshansky, and G.Y. Lip Factors affecting quality of oral anticoagulation control among patients with atrial fibrillation on warfarin. The SAMe-TT2R2 score Chest 144 2013 1555 1563
34. R.R. Abumuaileq, E. Abu-Assi, S. Raposeiras-Roubin, and et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists Europace 17 7 2015 711 717
35. S. Windecker, P. Kolh, F. Alfonso, and et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur. Heart J. 35 2014 2541 2619
36. S. Hohnloser, J. Oldgren, S. Yang, and et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial Circulation 125 2012 669 676
37. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events. Meta-analysis of noninferiority randomized controlled trials Arch. Intern. Med. 172 2012 397 402
38. F.W. Verheugt Long-term oral anticoagulation in patients with coronary disease, and future developments Curr. Opin. Cardiol. 23 2008 315 319
39. T.B. Larsen, L.H. Rasmussen, F. Skjøth, and et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation. A prospective nationwide cohort study J. Am. Coll. Cardiol. 61 2013 2264 2273
40. D.J. Graham, M.E. Reichman, M. Wernecke, and et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation Circulation 131 2015 157 164
41. I.L. Holster, V.E. Valkhoff, E.J. Kuipers, and E.T.T.L. Tjwa New oral anticoagulants increase the risk for gastrointestinal bleeding: a systematic review and meta-analysis Gastroenterology 145 2013 105 112
42. K.A. Fox, J.P. Piccini, W. Wojdyla, and et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur. Heart J. 32 2011 2387 2394
43. R.P. Giugliano, C.T. Ruff, E. Braunwald ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 2013 2093 2104
44. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugs/AdvisoryCommittee/UCM20704.pdf
45. M.J. Alberts, J.W. Eikelboom, and G.J. Hankey Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation Lancet Neurol. 11 2012 1066 1081
46. B.N. Beasley, E.F. Unger, and R. Temple Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran N. Engl. J. Med. 364 2011 1788 1790
47. E.M. Hylek, D. Ko, and C.L. Cove Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation Thromb. Haemost. 111 2014 783 788
48. N.C. Chan, J.S. Paikin, J. Hirsh, M.N. Lauw, J.W. Eikelboom, and J.S. Ginsberg New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions Thromb. Haemost. 111 2014 798 807
49. US National Institutes of Health ClinicalTrials.gov. evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF who undergo PCI with stenting (RE-DUAL PCI) http//clinicaltrials.gov/ct2/show (Accessed August 14, 2014)